Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil
AUTOR(ES)
Pereira, Camila V, Tovo, Cristiane Valle, Grossmann, Thiago K, Mirenda, Henrique, Dal-Pupo, Bruna B, Almeida, Paulo RL de, Mattos, Angelo A de
FONTE
Mem. Inst. Oswaldo Cruz
DATA DE PUBLICAÇÃO
2016-04
RESUMO
There are about 350 million hepatitis B virus (HBV) carriers worldwide and chronic HBV is considered a major public health problem. The objective of the present study was to assess the effectiveness of the nucleos(t)ide analogues tenofovir (TDF) and entecavir (ETV) in the treatment of chronic HBV. A cross-sectional study was carried out from March-December 2013, including all patients with chronic HBV, over 18 years of age, undergoing therapy through the public health system in southern Brazil. Only the data relating to the first treatments performed with TDF or ETV were considered. Retreatment, co-infection, transplanted or immunosuppressed patients were excluded. Six hundred and forty patients were evaluated, of which 336 (52.5%) received TDF and 165 (25.8%) ETV. The other 139 (21.7%) used various combinations of nucleos(t)ide analogues and were excluded. The negativation of viral load was observed in 87.3% and 78.8% and the negativation of hepatitis B e antigen was achieved in 79% and 72% of those treated with ETV or TDF, respectively. Negativation of hepatitis B surface antigen was not observed. There was no occurrence of adverse effects. This is a real-life study demonstrating that long-term treatment with ETV and TDF is both safe and effective.
Documentos Relacionados
- Comparison of entecavir and adefovir for the treatment of chronic hepatitis B
- Efficacy of Entecavir therapy in elderly patients with chronic hepatitis B infection
- Profile of users of drugs for the treatment of chronic hepatitis B available through the Brazilian Public Health System
- Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B Patients in Brazil
- Potent Efficacy of Entecavir (BMS-200475) in a Duck Model of Hepatitis B Virus Replication